Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Gastroenterology
Published in: Current Treatment Options in Gastroenterology 4/2016

01-12-2016 | Motility (H Parkman and R Schey, Section Editors)

Novel Treatments for Cyclic Vomiting Syndrome: Beyond Ondansetron and Amitriptyline

Authors: Sanjay Bhandari, MD, Thangam Venkatesan, MD

Published in: Current Treatment Options in Gastroenterology | Issue 4/2016

Login to get access

Opinion statement

Cyclic vomiting syndrome (CVS) is a chronic functional gastrointestinal disorder that is characterized by episodic nausea and vomiting. Initially thought to only affect children, CVS in adults was often misdiagnosed with significant delays in therapy. Over the last decade, there has been a considerable increase in recognition of CVS in adults but there continues to be a lack of knowledge about management of this disorder. This paper seeks to provide best practices in the treatment of CVS and also highlight some novel therapies that have the potential in better treating this disorder in the future. Due to the absence of randomized control trials, we provide recommendations based on review of the available literature and expert consensus on the therapy of CVS. This paper will discuss prophylactic and abortive therapy and general measures used to treat an episode of CVS and also discuss pathophysiology as it pertains to novel therapy. Recent recognition of the association of chronic marijuana use with cyclic vomiting has led to the possibility of a new diagnosis called “Cannabinoid Hyperemesis Syndrome,” which is indistinguishable from CVS. The treatment for this purported condition is abstinence from marijuana despite scant evidence that marijuana use is causative. Hence, this review will also discuss emerging data on the role for the endocannabinoid system in CVS and therapeutic agents targeting the endocannabinoid system, which offer the potential of transforming the care of these patients.
Literature
1.
Abu-Arafeh I, Russell G. Cyclical vomiting syndrome in children: a population-based study. J Pediatr Gastroenterol Nutr. 1995;21(4):454–8.CrossRefPubMed
2.
Cullen KJ, Ma Cdonald WB. The periodic syndrome: its nature and prevalence. Med J Aust. 1963;50(2):167–73.PubMed
3.
Kumar N, Bashar Q, Reddy N, Sengupta J, Ananthakrishnan A, Schroeder A, et al. Cyclic vomiting syndrome (CVS): is there a difference based on onset of symptoms—pediatric versus adult? BMC Gastroenterol. 2012;12:52.CrossRefPubMedPubMedCentral
4.••
Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92 This paper describes Rome 1V criteria for various functional GI disorders (FGIDs) including cyclic vomiting syndrome. The paper was produced through a collaborative effort between the Rome foundation and Gastroenterology and is an update on Rome III criteria based on our evolving knowledge and understanding of FGIDs.CrossRefPubMed
5.•
Venkatesan T, Sengupta J, Lodhi A, Schroeder A, Adams K, Hogan WJ, et al. An Internet survey of marijuana and hot shower use in adults with cyclic vomiting syndrome (CVS). Exp Brain Res. 2014;232(8):2563–70 This paper examines the relationship between marijuan use, hot showers and CVS and shows that the hot showers were not pathognomic of marijuana.CrossRefPubMedPubMedCentral
6.
Fleisher DR, Gornowicz B, Adams K, Burch R, Feldman EJ. Cyclic vomiting syndrome in 41 adults: the illness, the patients, and problems of management. BMC Med. 2005;3:20.CrossRefPubMedPubMedCentral
7.
Li BU, Lefevre F, Chelimsky GG, Boles RG, Nelson SP, Lewis DW, et al. North American Society for Pediatric Gastroenterology, Hepatology, and nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr. 2008;47(3):379–93.CrossRefPubMed
8.
Namin F, Patel J, Lin Z, Sarosiek I, Foran P, Esmaeili P, et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil. 2007;19(3):196–202.CrossRefPubMed
9.
Hejazi RA, Reddymasu SC, Namin F, Lavenbarg T, Foran P, McCallum RW. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol. 2010;44(1):18–21.CrossRefPubMed
10.
Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, Fleisher DR, et al. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008;20(4):269–84.CrossRefPubMed
11.
Hejazi RA, Lavenbarg TH, Foran P, McCallum RW. Who are the nonresponders to standard treatment with tricyclic antidepressant agents for cyclic vomiting syndrome in adults? Aliment Pharmacol Ther. 2010;31(2):295–301.PubMed
12.
Clouse RE, Sayuk GS, Lustman PJ, Prakash C. Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series. Clin Gastroenterol Hepatol. 2007;5(1):44–8.CrossRefPubMed
13.
Olmez A, Kose G, Turanli G. Cyclic vomiting with generalized epileptiform discharges responsive to topiramate therapy. Pediatr Neurol. 2006;35(5):348–51.CrossRefPubMed
14.
Zaki EA, Freilinger T, Klopstock T, Baldwin EE, Heisner KR, Adams K, et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia. 2009;29(7):719–28.CrossRefPubMed
15.•
Venkatesan T, Zaki EA, Kumar N, Sengupta J, Ali M, Malik B, et al. Quantitative pedigree analysis and mitochondrial DNA sequence variants in adults with cyclic vomiting syndrome. BMC Gastroenterol. 2014;14:181. This study highlights some of the similarities and differences between adults and children with CVS. There was a lack of association between two mitochondrial DNA single nucleotide polymorphisms 16519T and 3010A and CVS in adults as opoosed to children. However, a subset of these patients had a high degree of matrilineal inheritance of functional disorders as seen in children.CrossRefPubMedPubMedCentral
16.
Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713–5.CrossRefPubMed
17.
Boles RG, Lovett-Barr MR, Preston A, Li BU, Adams K. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol. 2010;10:10.CrossRefPubMedPubMedCentral
18.
Van Calcar SC, Harding CO, Wolff JA. L-carnitine administration reduces number of episodes in cyclic vomiting syndrome. Clin Pediatr (Phila). 2002;41(3):171–4.CrossRef
19.
Boles RG. High degree of efficacy in the treatment of cyclic vomiting syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, a case series. BMC Neurol. 2011;11:102.CrossRefPubMedPubMedCentral
20.
Kowalczyk M, Parkman H, Ward L. Adult cyclic vomiting syndrome successfully treated with intranasal sumatriptan. J Gen Intern Med. 2010;25(1):88–91.CrossRefPubMed
21.
Kumar N, Gagan K, Schroeder A, Hogan WJ, Venkatesan T. Efficacy of nasal triptans as abortive therapy in adults with cyclic vomiting syndrome: a tertiary care experience. Gastroenterol. 2011;140:S463-S.
22.
Boles RG, Adams K, Ito M, Li BU. Maternal inheritance in cyclic vomiting syndrome with neuromuscular disease. Am J Med Genet A. 2003;120a(4):474–82.CrossRefPubMed
23.
Li BU. Cyclic vomiting syndrome and abdominal migraine: periodic syndromes with gastrointestinal symptoms. Int Semin Pediatr Gastroenterol Nutr. 2000;9(3):1–8.
24.
25.
Mantyh PW. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry. 2002;63(Suppl 11):6–10.PubMed
26.
Bilkei-Gorzo A, Zimmer A. Mutagenesis and knockout models: NK1 and substance P. Handb Exp Pharmacol. 2005;169:143–62.CrossRef
27.•
Cristofori F, Thapar N, Saliakellis E, Kumaraguru N, Elawad M, Kiparissi F, et al. Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome. Aliment Pharmacol Ther. 2014;40(3):309–17 This is the only study to determine the efficacy of aprepitant as a prophylactic agent in the treatment of CVS.CrossRefPubMed
28.
Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–7.CrossRef
29.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–4.CrossRefPubMed
30.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–5.CrossRefPubMed
31.
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.CrossRefPubMed
32.
Sugiura T, Kodaka T, Kondo S, Nakane S, Kondo H, Waku K, et al. Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. J Biochem. 1997;122(4):890–5.CrossRefPubMed
33.
Darmani NA. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. J Pharmacol Exp Ther. 2002;300(1):34–42.CrossRefPubMed
34.
Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterol. 2001;121(4):767–74.CrossRef
35.
Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010;376(9740):517–23.CrossRefPubMed
36.
Price SL, Fisher C, Kumar R, Hilgerson A. Cannabinoid hyperemesis syndrome as the underlying cause of intractable nausea and vomiting. J Am Osteopath Assoc. 2011;111(3):166–9.CrossRefPubMed
37.•
Venkatesan T, Zadvornova Y, Raff H, Hillard CJ. Endocannabinoid-related lipids are increased during an episode of cyclic vomiting syndrome. Neurogastroenterol Motil. 2016;28(9):1409–18. This paper is the first of its kind studying the role of the endocannabinoid system and the hypothalamic pituitary adrenal axis in adults with CVS and shows an increase in circulating concentrations of endocannabinoid-related lipids, N-oleoylethanolamine (OEA) and N-palmitoylethanolamide (PEA), during the sick phase of CVS, which positively correlates with CVS symptoms.CrossRefPubMed
38.
Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53(11):1566–70.CrossRefPubMedPubMedCentral
39.
40.
41.
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol—recent advances. Chem Biodivers. 2007;4(8):1678–92.CrossRefPubMed
42.•
Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014;722:134–46. This paper provides an excellent review of the role of the the endocannabinoid system in the regulation of nausea and vomiting and also discusses potential therepeutic implications.CrossRefPubMed
43.
Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, Piomelli D. The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav. 2009;97(1):121–4.CrossRefPubMedPubMedCentral
44.
Frey UH, Scharmann P, Lohlein C, Peters J. P6 acustimulation effectively decreases postoperative nausea and vomiting in high-risk patients. Br J Anaesth. 2009;102(5):620–5.CrossRefPubMed
45.
Werntoft E, Dykes AK. Effect of acupressure on nausea and vomiting during pregnancy. A randomized, placebo-controlled, pilot study. J Reprod Med. 2001;46(9):835–9.PubMed
46.
Hee W. Acupuncture in the treatment of hysterica mutism and functional vomiting. Med J Malaysia. 1978;33(2):162–4.PubMed
47.
Hejazi RA, Lavenbarg TH, McCallum RW. Spectrum of gastric emptying patterns in adult patients with cyclic vomiting syndrome. Neurogastroenterol Motil. 2010;22(12):1298–302 e338.CrossRefPubMed
48.
Grover I, Kim R, Spree DC, Lahr CJ, Kedar A, Kothari S, et al. Gastric electrical stimulation as potential treatment in drug refractory cyclic vomiting syndrome. J Neurogastroenterol Motil. 2016. doi:10.​5056/​jnm15135.PubMedPubMedCentral
Metadata
Title
Novel Treatments for Cyclic Vomiting Syndrome: Beyond Ondansetron and Amitriptyline
Authors
Sanjay Bhandari, MD
Thangam Venkatesan, MD
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 4/2016
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-016-0114-y

Other articles of this Issue 4/2016

Current Treatment Options in Gastroenterology 4/2016 Go to the issue

Stomach (K Koch, Section Editor)

Gastric Electrical Stimulation for Gastroparesis and Chronic Unexplained Nausea and Vomiting

Motility (H Parkman and R Schey, Section Editors)

Opioids and GI Motility—Friend or Foe?

Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy

Motility (H Parkman and R Schey, Section Editors)

Gastrointestinal Transit Assessment: Role of Scintigraphy: Where Are We Now? Where Are We Going?

Stomach (K Koch, Section Editor)

Newest Drugs for Chronic Unexplained Nausea and Vomiting

Motility (H Parkman and R Schey, Section Editors)

Cannabinoids and GI Disorders: Endogenous and Exogenous

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits